scPharmaceuticals Inc. (SCPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
SCPH Stock Price Chart Interactive Chart >
SCPH Price/Volume Stats
|Current price||$6.00||52-week high||$9.64|
|Prev. close||$5.95||52-week low||$4.75|
|Day high||$6.51||Avg. volume||102,458|
|50-day MA||$5.78||Dividend yield||N/A|
|200-day MA||$6.24||Market Cap||164.13M|
scPharmaceuticals Inc. (SCPH) Company Bio
scPharmaceuticals Inc. engages in the development and commercialization of transformative pharmaceutical products. The company’s under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.
Most Popular Stories View All
SCPH Latest News Stream
|Loading, please wait...|
SCPH Latest Social Stream
View Full SCPH Social Stream
Latest SCPH News From Around the Web
Below are the latest news stories about scPharmaceuticals Inc that investors may wish to consider to help them evaluate SCPH as an investment opportunity.
scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021
Data show statistically significant and meaningful reduction in both heart failure-related and overall healthcare costs for patients treated with FUROSCIX® versus a historical comparator group Company on track to resubmit FUROSCIX NDA in the fourth quarter 2021 BURLINGTON, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies
scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright 23 rd Annual Global Investment Conference, being held virtually September 13-15, 2021.
Every investor in scPharmaceuticals Inc. ( NASDAQ:SCPH ) should be aware of the most powerful shareholder groups...
Received minutes from Type C meeting with the FDA confirming alignment on path toward resubmission of FUROSCIX ® NDA; no additional clinical data or device modifications required at this time; on track for resubmission in Q4
scPharma''s Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients
scPharmaceuticals Inc (NASDAQ: SCPH ) announced top-line results from its FREEDOM-HF study evaluating overall and heart failure-related costs of treating congestion in patients with chronic heart failure. Patients were treated with the Company''s investigational Furoscix, post-discharge from the emergency department, compared to a historical comparator group treated with intravenous furosemide in the inpatient hospital setting. Due to a Full story available on Benzinga.com
SCPH Price Returns